Human interleukin-2
- Generic Name
- Human interleukin-2
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- FNO32LO217
- Background
Human interleukin-2 is under investigation in clinical trial NCT03475134 (TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in mMEL).
- Associated Conditions
- -
- Associated Therapies
- -
TIL Therapy in Metastatic Melanoma and IL2 Dose Assessment
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 2
- Registration Number
- NCT01995344
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
- Conditions
- Interventions
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT01937468
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Insitute, Boston, Massachusetts, United States
In Vivo Treg Expansion and Graft-Versus-Host Disease Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2013-08-22
- Last Posted Date
- 2017-07-02
- Target Recruit Count
- 20
- Registration Number
- NCT01927120
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2021-08-23
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT01896271
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 3
- Registration Number
- NCT01883297
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Therapy for Children With Advanced Stage Neuroblastoma
- Conditions
- Interventions
- Drug: cyclophosphamideDrug: topotecanBiological: hu14.18K322AProcedure: peripheral blood stem cell harvestProcedure: surgical resectionDrug: cisplatinDrug: etoposideDrug: doxorubicinDrug: vincristineDrug: busulfanDrug: melphalanBiological: peripheral blood stem cell transplantationBiological: natural killer cell infusionRadiation: radiation therapyBiological: GM-CSFBiological: G-CSFDrug: mesnaDrug: levetiracetamBiological: interleukin-2Drug: IsotretinoinDevice: CliniMACS
- First Posted Date
- 2013-05-20
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 153
- Registration Number
- NCT01857934
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Evaluation of the Efficacy and Tolerability of Treatment With Interleukin-2 in Severe and Resistant Alopecia Areata
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Centre Hospitalier Universitaire de Nice
- Target Recruit Count
- 4
- Registration Number
- NCT01840046
- Locations
- 🇫🇷
CHU de Nice - Hôpital Archet, Nice, Alpes-Maritimes, France
Interleukin-2 in Metastatic Kidney Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-02-08
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 7
- Registration Number
- NCT01702909
- Locations
- 🇺🇸
Western Regional Medical Center, Inc, Goodyear, Arizona, United States
Interleukin-2 in Metastatic Melanoma
- First Posted Date
- 2012-10-10
- Last Posted Date
- 2018-04-05
- Lead Sponsor
- Western Regional Medical Center
- Target Recruit Count
- 8
- Registration Number
- NCT01702896
- Locations
- 🇺🇸
Western Regional Medical Center, Inc., Goodyear, Arizona, United States
Systemic Therapy With Interferon, Interleukin-2 and BRAF Inhibitor
- First Posted Date
- 2012-05-22
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01603212
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.